Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

cts receive Traficet-EN. Patients who achieve a pre-specified reduction in disease severity are re-randomized to active drug or placebo for an additional 36-week 'Maintenance Period', thereby permitting an evaluation of the drug's ability to maintain a treatment response.

Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system.

About Traficet-EN(TM) (CCX282-B)

Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 clinical trial in Crohn's disease, Traficet-EN is being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role. ChemoCentryx has completed five Phase I clinical trials and one four-week Phase II Crohn's disease trial of Traficet-EN, demonstrating that the product candidate is well-tolerated and appropriate for once-daily oral dosing. Traficet-EN may offer advantages
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015  NanoSmart ... drug delivery platforms, has received Orphan Drug Designation ... a second drug product that uses NanoSmart,s proprietary ... formulation of dactinomycin for the treatment of Ewing,s ... The FDA granted NanoSmart,s Orphan Drug Designation on ...
(Date:7/30/2015)...  Cleave Biosciences today announced that the United ... company a key patent providing the protection of ... This newly issued patent, "Fused pyrimidines and ... allows for claims on the composition of matter ... of p97, a critical enzyme that controls various ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
... , MOUNTAIN VIEW, Calif., Dec. 18 ... of Ruediger Naumann-Etienne to its Board of Directors. , "Rudi ... medical device companies," said Theodore A. Boutacoff, President and CEO ... & Quist followed by CEO/President positions with Diasonics, OEC Medical ...
... Dec. 18 Eli Lilly and Company (NYSE: ... and chief financial officer for Lilly, has assumed expanded responsibilities ... and chief financial officer, effective January 1. , In ... officer of the company and add responsibility for global services, ...
Cached Medicine Technology:Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors 2Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors 3Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President 2
(Date:7/30/2015)... ... 30, 2015 , ... Boston Web Marketing is ... Google Partners is the platform for search marketing agencies to communicate with the ... necessary to run successful search marketing campaigns. Google Partners also affords businesses the ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ocean Hills Recovery has officially been accredited ... “no recommendations.” No recommendations means CARF found no areas in the OHR program that ... than 3% of all facilities receive. In addition, Ocean Hills was granted the maximum ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... National Cancer Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn ... (NCI)-designated cancer center. TCI joins an elite group of 69 cancer institutions nationwide ...
(Date:7/30/2015)... ... 30, 2015 , ... 1Heart Caregiver Services LLC is offering its 1st Business ... in the Booming Homecare Business.” This will be held in its main headquarters at ... event will be hosted by 1Heart’s very own Randy Clarito (Director of Business and ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Summer is ... hot spots.”* Add to that a particularly long, dry and hot 2015 summer season ... host and fresh water advocate Sharon Kleyne will discuss the 2015 summer season and ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3
... at the Medical Research Council have identified changes in ... in the esophagus, a condition called Barrett,s dysplasia, making ... before they develop into esophageal cancer. These findings, reported ... implications for patients and may help to monitor their ...
... new technology developed by neuroscientists at Cold Spring Harbor Laboratory ... made of whole brains. Until now, means of obtaining ... mammalian brain -- have been painstakingly slow and available only ... By automating and standardizing the process in which brain samples ...
... (HealthDay News) -- When women seem scarce, men may compete ... according to a new study. "What we see in ... more competitive. They compete more for access to mates," lead ... Carlson School of Management at the University of Minnesota, said ...
... FRIDAY, Jan. 13 (HealthDay News) -- Health and fitness experts ... by flogging long-range benefits such as losing weight or avoiding ... been going about it all wrong. Research now appears to ... effective message than "feel better now." A University of ...
... indices to identify patients with symptoms associated with ovarian cancer who ... the US in an attempt to promote earlier diagnosis, but they ... cancer, according to a study published January 13 in the ... cancer is a disease which is perceived to rarely produce symptoms ...
... wearing contact lenses affects glaucoma measurements has been named ... of Medicine,s annual St. Albert,s Day research symposium. ... fourth-year student at Stritch School of Medicine. Brenner ... on retinal nerve fiber layer measurements, which ophthalmologists use ...
Cached Medicine News:Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:CSHL team introduces automated imaging to greatly speed whole-brain mapping efforts 2Health News:CSHL team introduces automated imaging to greatly speed whole-brain mapping efforts 3Health News:Do Men Flash Cash to Find a Mate? 2Health News:Need to Exercise More? Think How It Will Help You Now 2Health News:Need to Exercise More? Think How It Will Help You Now 3Health News:Predicting the value of indexing symptoms for ovarian cancer 2
... Eliminate the need for makeshift, modified ... Why waste time gathering parts when your ... need to deliver the utmost in Heliox ... therapy is fast becoming the standard of ...
... has been developing diverse medical ... years. Our medical-surgical products have ... innovation, quality and customer satisfaction. ... the Labtron® line of diagnostic ...
... nebulizer utilizing Vibrating Mesh Technology to ... suffering from Asthma, COPD or other ... product size and handy carrying case ... takes them. Powerful delivery comparable to ...
... deliver particulate humidity in the 3 to ... patients. For your convenience, Thera-Mist® nebulizers may ... sterile water., ,The P30000N, for normal ... with a total flow range of 68-24 ...
Medicine Products: